The healthcare industry is spending more than ever on AI — but according to executives from Oracle Health, HCA Healthcare and BJC Health, much of that investment could be wasted. During a panel this week at HFMA’s annual conference, they argued that no amount of sophisticated tech can overcome a broken, antiquated data foundation. The post Bot vs. Bot: Why Healthcare AI Progress Might Be Stuck appeared first on MedCity News .
(MedPage Today) -- A 2010 paper that linked hepatitis B vaccines in infant boys to an increased risk of autism diagnosis was retracted and another study by the same authors is under investigation. The study, published in the Journal of Toxicology...
(MedPage Today) -- Alcohol consumption during pregnancy has been on the rise in recent years, with some groups, like unmarried women and women in frequent distress, more likely to partake, CDC data showed. Responding to a survey, 15.2% of pregnant...
(MedPage Today) -- The FDA approved capivasertib (Truqap) in combination with abiraterone (Zytiga) and prednisone for PTEN-deficient prostate cancer, the agency announced on Friday. Approval stipulates use in metastatic hormone-sensitive prostate...
(MedPage Today) -- The FDA on Friday approved belzutifan (Welireg) plus pembrolizumab (Keytruda, Keytruda Qlex) as adjuvant therapy for renal cell carcinoma (RCC) with a clear cell component. Based on results from LITESPARK-022, the combination...
(MedPage Today) -- Several top pro athletes and their surgeons say a modern version of an old tool is shaving weeks off the recovery time for certain injuries. And some top doctors think this is only the beginning. Cy Young Award winners Tarik...
(MedPage Today) -- Firefighters responding to a blaze that destroyed a massive medical equipment warehouse in Northern California and sent embers flying for miles were hindered by sprinklers and hydrants that weren't working, authorities said Friday...
(MedPage Today) -- Scammers used the identity of Brian Druker, MD, the renowned leukemia researcher known for his work developing imatinib (Gleevec), to pitch ivermectin as a cancer cure. (OregonLive) A phase III trial involving lurbinectedin...
The tentative deal comes months after CVS Health reached a proposed settlement in the lawsuit alleging major pharmacy benefit managers are inflating insulin costs.
The Trump administration is floating a proposal to establish a permanent framework for the Medicare drug price negotiations, as enabled by the Inflation Reduction Act (IRA).
The Federal Trade Commission may be winding down its ongoing insulin case against the three largest pharmacy benefit managers, as court docs suggest the agency has reached an agreement with Optum Rx.